Reuters: J&J shopping its Noramco API unit for up to $800M deal

Noramco facility in Wilmington, DE--Courtesy of Noramco

Johnson & Johnson ($JNJ) is said to be shopping its API manufacturing unit Noramco in a deal that could fetch up to $800 million.

Citing sources "familiar" with the deal, Reuters said buyout firms appear to be the most interested in the division, which manufactures the active ingredients in painkillers like oxycodone. The unit had annual earnings before interest, taxes, depreciation and amortization of more than $70 million.

The source declined to be identified due to the confidential nature of the sale talks. Johnson and Johnson officials also declined to comment to the news service.

In 2014, GlaxoSmithKline ($GSK) and Johnson & Johnson, which control most of the needed opium supplies for the industry, began lobbying authorities to approve genetic engineering so opium farming can be both expanded and made less susceptible to pests and so they can assure their customers they can keep up with demand.

Tasmania produces about 85% of the global supply of thebaine, the opium poppy extract used to make Oxycontin and other similar drugs. It produces all of the oripavine in the world, used to make treatments for heroin overdoses. It produces 25% of the world supply of morphine and codeine, which continue to be used widely outside of the U.S.

- read the Reuters story

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

Roche's global manufacturing leader Pierre-Alain Ruffieux will take the reins and oversee the Moderna COVID-19 vaccine collaboration.